PTPN11 and melanoma: Inactivating variants in NF1, the most frequently mutated gene in melanoma after BRAF/NRAS/TP53, being reported in 10–15% of cases, were described in up to 46% of wild-type BRAF and RAS melanomas, in particular in male, older or chronically sun-exposed patients, and in copresence of mutations in RASopathy genes, e.g., PTPN11 and RASA2, that enhance its role in melanomagenesis, besides the RAS missing inhibition (Krauthammer et al., 2015).